Niacin, lipids, and heart disease

Current Cardiology Reports

Volumn 5, Issue 6, 2003, Pages 470-476

  Malik, Shaista ^b   Kashyap, Moti L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ANTIOXIDANT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; CERIVASTATIN; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; CYANOCOBALAMIN; DIACYLGLYCEROL ACYLTRANSFERASE; FIBRIC ACID DERIVATIVE; FOLIC ACID; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; MEVINOLIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINIC ACID; NICOTINURIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PYRIDOXINE; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; LIPOPROTEIN;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG USE; DYSLIPIDEMIA; ENZYME INHIBITION; HEART DISEASE; HOT FLUSH; HUMAN; LIPOLYSIS; LIVER; LIVER TOXICITY; MORTALITY; REVIEW; DRUG COMBINATION; DRUG EFFECT;

ANTILIPEMIC AGENTS; DRUG THERAPY, COMBINATION; HEART DISEASES; HUMANS; LIPOPROTEINS; NIACIN;

EID: 1542780828     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-003-0109-x     Document Type: Review

References (48)

1. The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals. Edited by Budavari S, O'Neil MJ, Smith A, Heckelman PE. Whitehouse Station, NJ: Merck Publishing Group; 1989:1030-1031.
2. Morgan MM, Capuzzi DM, Guyton JR: A new extended release niacin (Niaspan): efficacy, tolerability and safety in hypercholesterolemic patients. Am J Cardiol 1998, 82:29U-34U.
3. Knopp RH, Alagona P, Davidson M, et al.: Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998, 47:1097-1104.
4. Tavintharan S, Kashyap ML: The benefits of niacin in atherosclerosis. Curr Atherosclerosis Rep 2001, 3:74-82.
5. Capuzzi DM, Guyton JR, Morgan JM, et al.: Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 1998, 82:74U-81U.
6. Guyton JR, Goldberg AC, Kreisberg RA, et al.: Effectiveness of once-daily dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998, 82:737-743.
7. Sakai T, Kamanna VS, Kashyap ML: Niacin but not gemfibrozil increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL-cholesterol. Arterioscler Thromb Vasc Biol 2001, 21:1783-1789.
8. Knopp RH, Alagona P, Davidson M, et al.: Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998, 47:1097-1104.
9. Mckenney JM, Proctor JD, Harris S, Chinchili VM: A comparison of the efficacy and toxic effects of sustained- vs. immediate-release niacin in hypercholesterolemic patients. JAMA 1994, 271:672-677.
10. Knopp RH, Ginsberg J, Albers JJ, et al.: Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues of mechanism of action of niacin. Metabolism 1985, 34:642-650.
11. Stern RH, Freeman D, Spence JD: Differences in metabolism of time-release and unmodified nicotinic acid: explanation of the differences in hypolipidemic action. Metabolism 1992, 41:879-881.
12. Blankenhorn DH, Nessim SA, Johnson RL, et al.: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987, 257:3233-3240.
13. Knopp RH: Evaluating niacin in its various forms. Am J Cardiol 2000, 86(Suppl):51L-56L.
14. Advicor prescribing information. Miami: Kos Pharmaceuticals; 2001.
15. Superko HR, Krauss RM: Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis 1992, 95:69-76.
16. McKenney JM, McCormick LS, Schaeffer EJ, et al.: Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol 2001, 88:270-274.
17. Kashyap ML, McGovern ME, Berra K, et al.: Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002 89:672-678.
18. Guyton JR, Blazing BA, Hagar J, et al., for the Niaspan-Gemfibrozil Study Group: Extended release niacin vs. gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Arch Intern Med 2000, 160:1177-1184.
19. Garg R, Malinow M, Pettinger M, et al.: Niacin treatment increase plasma homocyst(e)ine levels. Am Heart J 1999, 138:1082-1087.
20. Magoni AA, Jackson SH: Homocysteine and cardiovascular disease: Current perspective and future prospects. Am J Med 2002, 112:556-565.
21. Altschul R, Hoffer A, Stephen JD: Influence of nicotinic acid on serum cholesterol in man. Arch Bioch Biophys 1955, 54:558-559.
22. Carlson LA: Studies on the effect of nicotinic acid on catecholamine stimulated lipolysis in adipose tissue in vitro. Acta Med Scand 1963, 173:719-722.
23. Wise A, Foord SM, Fraser NJ, et al.: Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 2003, 278:9869-9874.
24. Tunaru S, Kero J, Schuab A, et al.: PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 2003, 9:352-355.
25. Jin FY, Kamanna VS, Kashyap ML: Niacin accelerates intracellular apo B degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (Hep G2) cells. Arterioscler Thromb Vasc Biol, 1999, 19:1051-1059.
26. Ganji SH, Tavintharan S, Zhu D, et al.: Niacin non-competitively inhibits hepatocyte diacylglycerol acyltransferase, a key enzyme for triglyceride synthesis [abstract]. Arterioscler Thromb Vasc Biol 2002, 22:878A.
27. Kamanna VS, Kashyap ML: Mechanism of action of niacin on lipoprotein metabolism. Curr Artherosclerosis Rep 2000, 2:36-46.
28. Blum CB, Levy JU, Eisenberg S, et al.: High density lipoprotein metabolism in man. J Clinc Invest 1977, 60:795-807.
29. Shepherd J, Packard CJ, Patsch JR, et al.: Effect of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest 1979, 63:858-867.
30. Jin FY, Kammana VS, Kashyap ML: Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 1997, 17:2020-2028.
31. Martinez LD, Jacquet S, Esteve JP, et al.: Ectopic b-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 2003, 421:75-79.
32. Moestrup SK, Kozyraki R: Cubilin, a high-density lipoprotein receptor. Curr Opin Lipidol 2000, 11:133-140.
33. The Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. JAMA 1975, 231:360-381.
34. Canner PL, Berge KG, Wenger NK, et al.: Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986, 8:1245-1255.
35. Carlson LA, Rosenhamer G: Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988, 223:405-418.
36. Blankenhorn DH, Nessim SA, Johnson RL, et al.: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987, 257:3233-3240.
37. Cashin-Hemphill L, Mack WJ, Pogoda JM, et al.: Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 1990, 264:3013-3017.
38. Brown G, Albers JJ, Fisher LD, et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990, 323:1289-1298.
39. Kane JP, Malloy MJ, Ports TA, et al.: Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990, 264:3007-3012.
40. Brown BG, Zhao X-Q, Chait A, et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583-1592; editorial 1636-1637.
41. Elam MB, Hunninghake DB, Davis KB, et al: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral vascular disease. The ADMIT study, a randomized trial. JAMA 2000, 284:1263-1270.
42. Grundy SM, Vega GL, McGovern ME et al.: Efficacy, safety and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002, 162:1568-1576.
43. Canner PL, Furberg CD, Terrin ML, McGovern ME: Niacin decreases myocardial infarction and total mortality in patients with metabolic syndrome: results from the coronary drug project [abstract]. J Amer Coll Card 2003, 41A.
44. LaRosa JC, He J, Vupputuri S: Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999, 282:2340-2346.
45. Rubins HB, Robins SJ, Collins D, et al.: Distribution of lipids in 8,500 men with coronary artery disease. Am J Cardiol 1995, 75:1196-1201.
46. Martin G, Duez H, Blanquart C, et al.: Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 2001, 107:1423-1432.
47. Qin S, Koga T, Ganji SH, et al.: Rosuvastatin stimulates apolipoprotein-AI synthesis but not HDL catabolism by human hepatoblastoma cells (Hep G2). Poster presented at the 4th annual Arteriosclerosis, Thrombosis, and Vascular Biology meeting. Washington, DC: May 8-10, 2003.
48. Bays HE, Dujovne CA, McGovern ME, et al.: Advicor versus other cholesterol-modulating agents trial evaluation. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the Advicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol 2003, 91:667-672.